Affordable Access

Publisher Website

Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application

Authors
Journal
Nanomedicine Nanotechnology Biology and Medicine
1549-9634
Publisher
Elsevier
Volume
10
Issue
3
Identifiers
DOI: 10.1016/j.nano.2013.10.003
Keywords
  • Cancer
  • Nanomaterials
  • Boron-Carrier
  • Folic Acid
  • Blood Cells
  • Erythrocytes
  • Hemolysis
  • Neutrophils
  • Platelet Aggregation
Disciplines
  • Medicine

Abstract

Abstract Boron neutron capture therapy (BNCT) is a radiotherapy treatment based on the accumulation in the tumor of a 10B-containing drug and subsequent irradiation with low energy neutrons, which bring about the decay of 10B to 7Li and an α particle, causing the death of the neoplastic cell. The effectiveness of BNCT is limited by the low delivery and accumulation of the used boron-containing compounds. Here we report the development and the characterization of BPO4 nanoparticles (NPs) as a novel possible alternative drug for BNCT. An extensive analysis of BPO4 NP biocompatibility was performed using both mature blood cells (erythrocytes, neutrophils and platelets) and a model of hematopoietic progenitor cells. A time- and concentration-dependent cytotoxicity study was performed on neoplastic coloncarcinoma and osteosarcoma cell lines. BPO4 functionalization with folic acid, introduced to improve the uptake by tumor cells, appeared to effectively limit the unwanted effects of NPs on the analyzed blood components.

There are no comments yet on this publication. Be the first to share your thoughts.